# Calidi Biotherapeutics to Present Preclinical Data for RedTail Virotherapy Platform at ESMO 2026

- URL: https://stocks.freetheai.org/news/calidi-biotherapeutics-to-present-preclinical-data-for-redtail-virotherapy-0d0ec7
- Published: 2026-10-19T12:00:00Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [AMEX:CLDI](https://stocks.freetheai.org/symbols/AMEX-CLDI)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Calidi Biotherapeutics, Inc. (CLDI) announced plans to present preclinical data on its proprietary RedTail virotherapy platform at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, scheduled for October 23-27, 2026. The presentations on October 24 will feature data on the company's lead candidate, CLD-401, alongside candidates from its in situ T-cell engager (TCE) platform, including TROP-2-targeted CLD-501 and EpCAM-targeted CLD-502.

The upcoming presentations highlight progress across Calidi's oncology pipeline. Preclinical results for CLD-401 demonstrate high rates of tumor eradication in breast cancer mouse models and effective antitumor activity in bladder cancer models using both intravenous and localized administration. Meanwhile, laboratory studies of the dual-payload TCE candidates showed dose-dependent T-cell cytotoxicity while maintaining full payload expression, offering a potential strategy to overcome toxicity and drug delivery obstacles in solid tumor treatment.

Investors and industry observers will look for full data disclosures during the congress poster sessions on October 24, 2026. Calidi is currently conducting IND-enabling studies for CLD-401 in non-small cell lung cancer, head and neck cancer, and other advanced tumor types, while actively pursuing strategic partnerships to advance its platform into clinical testing.

## Key points

- Calidi Biotherapeutics, Inc. (CLDI) will present preclinical data on its RedTail virotherapy platform at ESMO Congress 2026 on October 24, 2026.
- Lead candidate CLD-401 achieved complete tumor eradication in breast cancer mouse models and demonstrated antitumor activity in bladder cancer models.
- Preclinical results for TCE candidates CLD-501 and CLD-502 showed dose-responsive T-cell cytotoxicity without compromising co-expressed payloads.
- CLD-401 is progressing through IND-enabling studies for non-small cell lung cancer, head and neck cancer, and other solid tumor indications.
- Calidi is actively seeking strategic partnerships to accelerate the clinical development of its RedTail platform.

## Questions and answers

### What is Calidi Biotherapeutics presenting at ESMO 2026?

Calidi Biotherapeutics is presenting preclinical data on its RedTail virotherapy platform, including lead program CLD-401 and In Situ TCE candidates CLD-501 and CLD-502, at ESMO Congress 2026 on October 24, 2026.

### What preclinical results were reported for CLD-401?

CLD-401 showed complete tumor eradication in breast cancer mouse models and retained antitumor activity in bladder cancer models following both systemic intravenous and localized intratumoral administration.

### What indications is Calidi pursuing with CLD-401?

Calidi is conducting IND-enabling studies for CLD-401 to treat metastatic non-small cell lung cancer, head and neck cancer, and other solid tumor types with high unmet medical need.